A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom
- Registration Number
- NCT02265393
- Lead Sponsor
- Otonomy, Inc.
- Brief Summary
This is a 2-part study of OTO-104 in subjects with unilateral Meniere's disease in the United Kingdom. The first part is a randomized, placebo-controlled study comparing the safety profile of 2 injections of OTO-104 or placebo spaced 3 months apart. The second part is an open-label extension where all subjects will receive an additional 2 intratympanic injections of OTO-104 spaced 3 months apart. Each subject will participate on the study for a total of 1 year.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 128
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo OTO-104 vehicle OTO-104 OTO-104 12 mg OTO-104 (dexamethasone)
- Primary Outcome Measures
Name Time Method Safety Up to 1 Year Otoscopy, audiometry, tympanometry, adverse events
- Secondary Outcome Measures
Name Time Method Meniere's Symptom Questionnaire Up to 1 Year
Trial Locations
- Locations (15)
Heatherwood & Wexham Park Hospitals
🇬🇧Berkshire, United Kingdom
Birmingham University Hospital
🇬🇧Birmingham, United Kingdom
BMI The Edgbaston Hospital
🇬🇧Birmingham, United Kingdom
Southmead Hospital Bristol
🇬🇧Bristol, United Kingdom
Oxford University Hospitals
🇬🇧Bucks, United Kingdom
Cambridge University Hospitals
🇬🇧Cambridge, United Kingdom
Dorset County Hospital
🇬🇧Dorset, United Kingdom
Gloucestershire Royal Hospital
🇬🇧Gloucester, United Kingdom
Leicester Royal Infirmary
🇬🇧Leicestershire, United Kingdom
Guy's Hospital and St. Thomas' Hospital
🇬🇧London, United Kingdom
Scroll for more (5 remaining)Heatherwood & Wexham Park Hospitals🇬🇧Berkshire, United Kingdom